A long war begins: Biosimilars versus patented biologics

Journal of Medical Economics

Volumn 18, Issue 12, 2015, Pages 1071-1073

  Bocquet, François ^a,b,c   Paubel, Pascal ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Biologics; Biosimilars; Epoetin; Generics; Granulocyte Colony; Monoclonal antibodies; Stimulating Factor

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR AGENT;

CHRONIC DISEASE; DIABETES MELLITUS; DRUG MARKETING; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; FUNDING; GOVERNMENT REGULATION; HEALTH CARE COST; HUMAN; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; PATENT; REVIEW; RHEUMATIC DISEASE; COMPARATIVE STUDY; COST CONTROL; ECONOMICS; PROCEDURES; STANDARDS;

BIOLOGICAL PRODUCTS; BIOSIMILAR PHARMACEUTICALS; COST SAVINGS; HUMANS;

EID: 84941363882     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1075996     Document Type: Review

References (11)

1. Haustein R, de Millas C, Hoër A et al. Saving money in the European healthcare systems with biosimilars. Generics Biosimilars Initiat J 2012;1:120-6
2. What you need to know about biosimilar medicinal products: process on corporate responsibility in the field of pharmaceuticals access to medicines in Europe. European Commission. Consensus Information Paper, 2013. http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars- report-en.pdf
3. Grabowski HG, Ridley DB, Schulman KA. Entry and competition in generic biologicals. Manag Decis Econ 2007;28:439-51
4. Schellekens H. How similar 'biosimilars' need to be? Nat Biotechnol 2004;22:1357-9
5. Simoens S. Health economics of market access for biopharmaceuticals and biosimilars. J Med Econ 2009;12:211-18
6. Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscape. IMS Health Whitepaper, 2011. http://www.imshealth. com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars- Whitepaper.pdf. Accessed 2015 April 27
7. FDA News Release - FDA approves first biosimilar product Zarxio, March 6, 2015. U.S. Food and Drug Administration, 2015. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm. Accessed 2015 April 12
8. Bocquet F, Paubel P, Fusier I et al. Biosimilar Granulocyte-Stimulating factor uptakes in the EU-5 Markets: a descriptive analysis. Appl Health Econ Health Policy 2014;12:315-26
9. Grabowski H, Guha R, Salgado M. Biosimilar competition: lessons from Europe. Nat Rev 2014;13:99-100s
10. Bocquet F, Paubel P, Fusier I et al. Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience. Appl Health Econ Health Policy 2015;13:47-59
11. Glaeske G, Schicktanz C, Barmer GEK. Arzneimittel report 2011 Bremen: Universität Bremen. Abteilung für Gesundheitsökonomie, Gesundheitspolitik und Versorgungs-forschung, 2011. http://www.zes.uni-bremen.de/uploads/ News/2011/110713-Kurzfassung.pdf Accessed 2015 April 10